<DOC>
	<DOCNO>NCT00051038</DOCNO>
	<brief_summary>The purpose clinical research study assess safety effectiveness entecavir , add lamivudine , treatment adult chronic hepatitis B infection co-infected HIV .</brief_summary>
	<brief_title>Study Adding Entecavir Current Lamivudine Therapy HIV HBV Co-Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Documented history coinfection HIV HBV Stable Anti Retroviral Therapy regimen contain lamivudine 150 mg BID least 24 week prior enrollment ; Documented HBV viremia screen least 4 week prior screen HBe Agpositive HBe Agnegative / antiHBepositive HIV viral load 400 copies/mL Roche Amplicor ( TM ) 1.5 HIV PCR assay screen equally low least 12 week prior screen Absence CoInfection hepatitis C virus ( HCV ) hepatitis D virus ( HDV ) Absence form liver disease e.g. , alcoholic , autoimmune , biliary disease Less 1/2 week prior therapy nucleoside/nucleotide analogue ( exclude lamivudine ) activity HBV ( include e.g . famciclovir , tenofovir , ganciclovir , adefovir ) . No receipt therapy within 24 week prior randomization study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>